FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial.
Saved in:
| Title: | FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial. |
|---|---|
| Authors: | Rojo F; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Department of Pathology, Fundacion Jimenez Diaz University Hospital Health Research Institute (IIS-FJD, UAM)-CIBERONC, Madrid, Spain., Taylor CR; Onconostic Technologies, Inc. (OT), Evanston, Illinois., Barrios C; LACOG, Latin American Cooperative Oncology Group, Porto Alegre, Brazil.; Centro de Pesquisa Clinica Hospital São Lucas da PUCRS, Porto Alegre, Brazil., Torrecillas L; LACOG, Latin American Cooperative Oncology Group, Porto Alegre, Brazil.; Centro Medico Nacional 20 de Noviembre ISSSTE, CDMX, Porto Alegre, Mexico., Ruiz-Borrego M; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital Universitario Virgen del Rocio, Sevilla, Spain., Perez-Buira S; Department of Pathology, Fundacion Jimenez Diaz University Hospital Health Research Institute (IIS-FJD, UAM)-CIBERONC, Madrid, Spain., Bines J; LACOG, Latin American Cooperative Oncology Group, Porto Alegre, Brazil.; National Cancer Institute (INCA), Brazil., Guerrero-Zotano A; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Instituto Valenciano de Oncologia (IVO), Valencia, Spain., Garcia-Saenz JA; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Department of Oncology and Instituto de Investigacion Sanitaria Hospital Clinico San Carlos (IdISSC), Madrid, Spain., Torres R; LACOG, Latin American Cooperative Oncology Group, Porto Alegre, Brazil.; Instituto Nacional del Cancer, Santiago, Chile., de la Haba-Rodriguez J; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC)-Hospital Universitario Reina Sofia, Universidad de Cordoba, Cordoba, Spain.; Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain., Ayala F; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital General Universitario Morales Meseguer, Murcia, Spain.; Department of Medical Oncology, Hospital General Universitario Gregorio Marañon Instituto de Investigacion Sanitaria Gregorio Marañon, Madrid, Spain., Gomez H; LACOG, Latin American Cooperative Oncology Group, Porto Alegre, Brazil.; Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru.; Universidad Ricardo Palma, Lima, Peru., Llombart A; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital Arnau de Vilanova, Valencia, Spain., Rodriguez de la Borbolla M; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital de Valme, Sevilla, Spain., Baena-Cañada JM; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital Universitario Puerta del Mar, Instituto de Investigacion e Innovacion Biomedica de Cadiz (INIBICA), Cadiz, Spain., Barnadas A; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Calvo L; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain., Herranz J; GEICAM, Spanish Breast Cancer Group, Madrid, Spain., Rincon R; GEICAM, Spanish Breast Cancer Group, Madrid, Spain., Caballero R; GEICAM, Spanish Breast Cancer Group, Madrid, Spain., Bermejo B; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain.; Medicine Department, Hospital Clinico Universitario de Valencia, Instituto de Investigacion Sanitaria (INCLIVA), Universidad de Valencia, Valencia, Spain., Ray PS; Onconostic Technologies, Inc. (OT), Evanston, Illinois., Martin M; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain.; Department of Medical Oncology, Hospital General Universitario Gregorio Marañon Instituto de Investigacion Sanitaria Gregorio Marañon, Madrid, Spain.; Universidad Complutense, Madrid, Spain. |
| Corporate Authors: | GEICAM_CIBOMA Clinical Trial Group |
| Source: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Sep 02; Vol. 31 (17), pp. 3715-3724. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
